Company Encyclopedia
View More
name
iShares Healthcare Innovation UCITS ETF
HEAL.UK
News
View More

SkylineDx's Merlin CP-GEP Test outperforms competitor test in melanoma risk stratification, showing stronger predictive accuracy for SLNB outcomes.

Recent data analysis has debunked inaccurate benchmarks released by a competitor, with SkylineDx's separate analysis showcasing that the Merlin CP-GEP Test offers more robust metastatic-risk stratification and better predictive accuracy for SLNB outcomes compared to the 31-GEP/i31-SLNB method. This was found through a comprehensive evaluation...

Unusual Whales·
Unusual Whales·

New study finds 300 mg monthly buprenorphine dose better than 100 mg for opioid abstinence, well-tolerated.

Monthly maintenance doses of 100 mg and 300 mg showed positive results in promoting opioid abstinence, being well-received with no additional safety concerns noted. Further analysis revealed that the 300-mg dose was notably more effective than the 100-mg dose in participants, indicating its superiority in the study.

Unusual Whales·
Unusual Whales·

Sterilization Monitoring Market expects to reach $1.51 billion by 2032 driven by real-time data platforms, regulatory expectations, and diverse industrial use.

A recently added report titled "Sterilization Monitoring Market - Global Forecast 2025-2032" on ResearchAndMarkets.com highlights the growing importance of the sterilization monitoring market. This sector is crucial for organizations within healthcare, pharmaceuticals, biotechnology, and food processing industries to maintain safe, compliant, and efficient operations. With the rise in complexity of sterilization procedures, there is a heightened demand for advanced monitoring solutions to ensure safety and efficacy. This report provides valuable insights and forecasts for this market segment.

Unusual Whales·
Unusual Whales·

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy

Vial's INHBE siRNA, a first-in-class liver-targeted therapy, is gaining praise from key opinion leaders for its potential in obesity treatment. This therapy targets INHBE to promote fat-selective weight loss while preserving lean muscle mass. It is being explored as both a mono-therapy and in combination with GLP-1s, offering flexibility in weight management. Experts highlight its novel mechanism and potential to improve body composition, making it a promising next-generation obesity therapy.

biopharmadive·
biopharmadive·

Gene therapies for cardiomyopathies market set for rapid expansion (2025-2034) fueled by advancements in AAV and CRISPR platforms, including potential candidates like LX2020 and LX2006.

The market for gene therapies targeting cardiomyopathies is experiencing significant growth due to advancements in genomic medicine that are driving the creation of tailored treatments for both inherited and acquired heart conditions. Promising candidates like LX2020 and LX2006 from Lexeo indicate further progress in this field. This growth trend is expected to continue as the market evolves, with potential to reach substantial numbers in terms of revenue and impact on patient outcomes.

Unusual Whales·
Unusual Whales·
© 2025 Longbridge｜Disclaimer